Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data EyePoint, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
7.54
2.96
4.57
20.4
34.4
36.9
41.4
46
43.3
31.4
Research and development
14.9
16.2
18.5
15.4
17.4
28.5
49.6
64.7
133
221
Selling and marketing
0
1.51
9.66
29.8
25.3
27.5
25.5
11.7
0.13
0.09
General and administrative
11.2
11.5
15.4
17.9
20.7
25.6
34.8
40.1
52.4
51.6
Operating expenses
26.1
29.2
43.6
68.2
71.7
92.2
141
121
189
275
Operating income
-18.6
-26.3
-39
-47.9
-37.3
-55.3
-99.6
-75.1
-146
-243
Interest expense
0
0.72
2.36
6.18
7.26
5.5
3.19
1.25
0.01
0.03
Other non-operating income
0.09
-26.9
0.42
-8.93
-8.1
-3.14
-2.62
4.36
15.1
11.8
Pre-tax income
-18.5
-53.2
-56.8
-45.4
-58.4
-102
-70.7
-131
-232
Income tax
0
0
0
0
0
0
0.08
0.09
0.28
Net income
-18.5
-53.2
-86.1
-56.8
-45.4
-58.4
-102
-70.8
-131
-232
EBITDA
-18.5
-26.1
-47.7
-37.1
-55
-99.2
-74.6
-144
-241
EPS, basic
-5.24
-11.59
-12.79
-5.44
-3.54
-2.03
-2.74
-1.82
-2.32
-3.17
EPS, diluted
-5.24
-11.59
-12.79
-5.44
-3.54
-2.03
-2.74
-1.82
-2.32
-3.17
Shares, basic (weighted)
3.51
4.59
6.74
10.4
12.8
28.8
37.3
0.04
0.06
0.07
Shares, diluted (weighted)
3.51
4.59
6.74
10.4
12.8
28.8
37.3
0.04
0.06
0.07
Balance sheet
FY2017
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
16.9
38.8
45.3
22.2
44.9
179
95.6
281
99.7
102
Short-term investments
0
33
48.9
49.8
271
204
Inventory
0
0
0.28
2.14
5.34
3.62
2.89
3.91
2.31
1.81
Other current assets
0.59
0.78
1.43
6
3.42
0.52
0.78
1.01
1.41
1.96
Total current assets
17.7
39.9
47.6
41.7
63.1
238
173
345
383
329
Property, plant and equipment
0.31
0.25
0.29
0.36
0.63
0.48
1.36
5.25
8.18
9.02
Lease right-of-use assets
0
3.08
2.61
2.25
6.04
4.98
21
20.2
Intangible assets
0.36
31.4
30.1
27.7
25.2
22.7
0
Other non-current assets
0
5.83
5.95
Total assets
18.7
71.7
78.2
73
91.7
263
180
355
418
364
Accounts payable
1.02
2.94
2.64
4.19
4.81
7.39
5.92
6.5
11.7
10.5
Accrued liabilities
4.22
3.72
3.79
6.83
8.45
14.4
16.4
17.5
18.1
24.4
Deferred revenue
0.05
0
0.03
0.02
0.95
1.07
1.21
38.6
17.8
0
Short-term debt
0
10.5
0
Total current liabilities
5.29
21.7
21.5
11.5
14.9
23.7
34.5
63.3
49
37
Long-term debt
0
17.3
17.6
47.2
38
36.6
29.3
Lease liabilities
0
2.9
2.33
1.86
5.98
4.91
21.9
20.8
Other non-current liabilities
0.05
1.23
1.46
3
2.37
2.35
0.6
0
0.21
0.09
Total liabilities
5.34
60
40.5
64.6
73.2
79
84
88.9
82
57.9
Total debt
0
17.3
17.6
47.2
38
36.6
30
Paid-in capital
323
375
445
473
528
753
767
1,008
1,208
1,410
Retained earnings
-311
-364
-408
-465
-511
-569
-671
-742
-873
-1,105
Other comprehensive income
0.83
0.84
0.84
0.84
0.84
0.84
0.79
0.86
1.03
0.96
Shareholders' equity
13.3
11.7
37.6
8.33
18.5
184
96.4
266
337
306
Total equity
13.3
11.7
37.6
8.33
18.5
184
96.4
266
337
306
Total liabilities and equity
18.7
71.7
78.2
73
91.7
263
180
355
418
364
Shares outstanding
3.91
7.4
9.47
10.9
18.1
33.9
34.1
49
68.3
82.8
Cash flow statement
FY2017
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-18.5
-53.2
-86.1
-56.8
-45.4
-58.4
-102
-70.8
-131
-232
Depreciation and amortization
0.09
0.17
0.14
0.19
0.31
0.4
0.46
1.54
2.31
Stock-based compensation
2.46
2.7
4.57
5.55
7.45
14.2
12.1
36.7
27.9
Deferred income tax
0.08
0.09
0.28
Change in inventory
0
0
-1.86
-3.2
1.35
-0.76
-1.55
1.6
0.49
Change in payables
-0.35
1.75
Cash from operations
-20.5
-21.9
-56.7
-14.4
-50.1
-65
1.88
-126
-240
Capital expenditures
-0.15
-0.11
-0.21
-0.36
-0.16
-2.15
-3.48
-4.05
-3.28
Acquisitions
0
-16.8
Purchases of investments
0
-33
-139
-55.1
-398
-252
Sales and maturities of investments
18.7
0
0
124
55.3
183
324
Cash from investing
13.6
-16.9
-0.21
-0.36
-33.1
-17.3
-3.32
-219
68.6
Debt issued
0
20
50
0
30
0
Debt repaid
-20
-13.8
0
-38.2
-30
0
Stock issued
8.4
41.5
22.6
49.9
0.37
0
226
163
173
Cash from financing
8.5
60.7
33.9
37.5
217
-0.69
187
164
174
Exchange rate effect
-0.01
0
0
0
0
Net change in cash
1.59
21.9
-23
22.7
134
-83
186
-182
2.12
Free cash flow
-20.6
-22
-56.9
-14.8
-50.3
-67.2
-1.61
-130
-243
Interest paid
0
0.26
4.87
5.51
4.85
2.6
1.41
0
Income taxes paid
0
0.1
0.2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.62 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-11,369.0%
Operating income / revenue.
EBITDA margin
-11,276.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-10,999.0%
Net income / revenue.
FCF margin
-9,730.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-9,587.0%
Cash from operations / revenue.
Return on equity (ROE)
-184.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-134.4%
Net income / average total assets.
Return on invested capital (ROIC)
-447.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
9,424.0%
Research and development expense / revenue.
Stock-based pay / revenue
1,263.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
142.8%
Capital expenditures / revenue.
D&A / revenue
93.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-27.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-8.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-1.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-9.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
47.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
75.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-13.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
26.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
31.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
30.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-87.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-64.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.50x
Current assets / current liabilities.
Quick ratio
4.30x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.30x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$32.22
Revenue / diluted weighted shares.
FCF per share
-$3,135.00
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3,089.00
Cash from operations / diluted weighted shares.
Book value per share
$1.96
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
112x
Market cap / revenue.
P/B
1.88x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.88x
Market cap / tangible book value, when positive.
EV/Sales
47.2x
Enterprise value / revenue.
FCF yield
-86.9%
Free cash flow / market cap.
Earnings yield
-98.3%
Net income / market cap (the inverse of P/E).
What was EyePoint, Inc.'s revenue in fiscal 2025?
EyePoint, Inc. reported revenue of $31.4M for fiscal 2025, 27.5% lower than the year before.
Was EyePoint, Inc. profitable in fiscal 2025?
No. It reported a net loss of $232.0M.
How much free cash flow did EyePoint, Inc. generate in fiscal 2025?
Cash from operations of $240.1M minus capital expenditures of $3.3M left free cash flow of -$243.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.